Form 4: Atlas Venture Funds Execute Stock Sales in Dyne Therapeutics (DYN) Under 10b5-1 Plans

Atlas Venture Funds, a significant shareholder in Dyne Therapeutics, executed multiple sales of common stock between February 26 and February 28, 2024, under pre-arranged Rule 10b5-1 trading plans.

Summary

• Atlas Venture Fund XI, L.P., Atlas Venture Opportunity Fund I, L.P., and Atlas Venture Opportunity Fund II, L.P. sold shares of Dyne Therapeutics (DYN) common stock between February 26 and February 28, 2024.
• The sales were executed under pre-arranged Rule 10b5-1 trading plans adopted on January 10, 2024.
• The transactions involved multiple sales at varying prices, with weighted average prices reported for each day.
• Atlas Venture Fund XI sold a total of 457,670 shares across the three days at prices ranging from $23.59 to $25.25.
• Atlas Venture Opportunity Fund I sold a total of 76,716 shares across the three days at prices ranging from $23.59 to $25.25.
• Atlas Venture Opportunity Fund II sold a total of 56,850 shares across the three days at prices ranging from $23.59 to $25.25.
• Following these transactions, Atlas Venture Fund XI directly holds 5,698,091 shares, Atlas Venture Opportunity Fund I directly holds 1,488,126 shares, and Atlas Venture Opportunity Fund II directly holds 864,487 shares.
• The reporting persons disclaim beneficial ownership of the securities held by the funds except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting transactions. The sales themselves could be interpreted as slightly negative, but the use of 10b5-1 plans mitigates this concern.

Risks

• Continued sales by major shareholders like Atlas Venture could exert downward pressure on Dyne Therapeutics' stock price.
• The reliance on Rule 10b5-1 plans suggests a predetermined strategy for selling shares, which may not be aligned with the company's long-term prospects.

Industry Context

Sales by major shareholders are a common occurrence in the biotech industry, especially after periods of significant stock appreciation or in accordance with pre-planned diversification strategies.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice for corporate insiders and major shareholders to sell shares while avoiding accusations of insider trading.
• The volume of shares sold is relatively small compared to the overall market capitalization of Dyne Therapeutics, suggesting a gradual liquidation strategy rather than a complete exit.

Stakeholder Impact

• The stock sales could potentially impact shareholder value if they create downward pressure on the stock price.
• The sales do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates